Toll Free: 1-888-928-9744

Chronic Urticaria Or Hives - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Urticaria Or Hives - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2017, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 4, 4 and 3 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Chronic Urticaria Or Hives - Overview Chronic Urticaria Or Hives - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Chronic Urticaria Or Hives - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development Biofrontera AG ELORAC Inc Faes Farma SA Fountain Biopharma Inc Genentech Inc GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Mycenax Biotech Inc Novartis AG Synermore Biologics Co Ltd Chronic Urticaria Or Hives - Drug Profiles BF-Derm-1 - Drug Profile Product Description Mechanism Of Action R&D Progress bilastine - Drug Profile Product Description Mechanism Of Action R&D Progress cetirizine hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress cidoxepin hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress GDC-0853 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2646264 - Drug Profile Product Description Mechanism Of Action R&D Progress ligelizumab - Drug Profile Product Description Mechanism Of Action R&D Progress omalizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress omalizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress omalizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress omalizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress omalizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress omalizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress omalizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress Chronic Urticaria Or Hives - Dormant Projects Chronic Urticaria Or Hives - Discontinued Products Chronic Urticaria Or Hives - Product Development Milestones Featured News & Press Releases Dec 19, 2016: Aralez Announces Commercial Launch Of BLEXTEN In Canada Nov 18, 2016: Taiho and Meiji Announce the Launch of Bilanoa Tablets 20 mg, an Oral Anti-allergy Drug in Japan Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN Nov 13, 2015: Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan May 25, 2015: Bilastine in Japan: Phase III trials completed and ready for registration Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Chronic Urticaria Or Hives, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H2 2017 Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H2 2017 Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H2 2017 Chronic Urticaria Or Hives - Pipeline by Fountain Biopharma Inc, H2 2017 Chronic Urticaria Or Hives - Pipeline by Genentech Inc, H2 2017 Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H2 2017 Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, H2 2017 Chronic Urticaria Or Hives - Pipeline by Novartis AG, H2 2017 Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H2 2017 Chronic Urticaria Or Hives - Dormant Projects, H2 2017 Chronic Urticaria Or Hives - Discontinued Products, H2 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify